The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Transforming patient outcomes in myeloma through real-time, SMS-based monitoring of symptoms & QoL
James Berenson, MD, Berenson Cancer Center, West Hollywood, CA, discusses the results of a feasibility study evaluating mQOL, a patient-reported outcome (PRO) platform for monitoring symptoms and quality of life (QoL) in patients with multiple myeloma through real-time, SMS-based reporting. Dr Berenson highlights the platform’s high engagement rate and ease of use, which enabled rapid identification of actionable events and informed clinical decisions to improve patient outcomes. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We conducted a feasibility study with a new patient-reported outcome platform called mQOL. To date, the patient-reported outcomes are very poorly reported. It’s cumbersome, it’s slow, it’s not all-inclusive, and most importantly, it’s not really done very frequently. With the mQOL platform, we’re able to do text messaging, easily done with patients of all ages and very quick to report to the PI, in this case me, within 24 hours, and then if there are changes, we contact patients to make clinical decisions to help them...
We conducted a feasibility study with a new patient-reported outcome platform called mQOL. To date, the patient-reported outcomes are very poorly reported. It’s cumbersome, it’s slow, it’s not all-inclusive, and most importantly, it’s not really done very frequently. With the mQOL platform, we’re able to do text messaging, easily done with patients of all ages and very quick to report to the PI, in this case me, within 24 hours, and then if there are changes, we contact patients to make clinical decisions to help them.
So the study was done among 58 consecutive patients in our clinic with newly diagnosed, relapsed/refractory, and on maintenance therapy. The average age was 68, slightly more men than women. The cadence was done so that these assessments were done on a daily basis for the first 28 days for patients with more active treatment, those either newly diagnosed or with relapsed/refractory disease, where it was every other week throughout the study for the patients who were on maintenance therapy. Those on frontline, and those patients who were left refractory after the first month, the next two months they were doing the cadence every other week. The total length of the study was 12 weeks. We looked at quality of life. We also looked at symptoms.
And the engagement was amazing. We had a completion rate of nearly 85% among these patients, and these patients were very, very easily engaged because it only took three minutes at a time, and then I got the data within a day, and then I got back to the patients if there were what we called actionable events, which occurred in 219 cases, in which there was an extreme change in some symptom, which we would act upon. So this new platform is much more user-friendly for the patient, quickly communicated to me, I can act on it, and also it helps to get more real data on what happens to patients between clinical visits. So I think the future is bright for using this platform to help our patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
